Background: Studies of adherence to breast cancer guidelines have often focused on primary therapies, but concordance with other guideline recommendations has not been examined as extensively. This study assesses the knowledge and practice patterns of medical oncologists in the United States to inform education and quality improvement initiatives that can improve breast cancer care. Methods: A survey containing case vignettes and related questions was developed to examine oncologists' clinical decision-making in evaluating and treating women with early breast cancer. The instrument was distributed to a random sample of 742 oncologists in the United States and yielded 205 responses (27.6% response rate). Responses from 184 practicing medical oncologists were analyzed relative to the 2007 NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Results: Most oncologists made guideline-consistent choices in clarifying indeterminate human epidermal growth factor 2 (HER2) status (85%), initial treatment for early breast cancer (95%), and postsurgical management of locally advanced breast cancer (82%). Guideline-discordant choices were seen in the lack of clip placement Breast cancer is the most common form of cancer (excluding non-melanoma skin cancers) among women, 1 and most oncologists routinely provide care for women with this disease. During the past decade, considerable changes have occurred in breast cancer management as new options for evaluating and managing breast tumors have become available. These innovations have contributed to a 2.2% annual decline in breast cancer mortality since 1990.
Breast cancer is the most common form of cancer (excluding non-melanoma skin cancers) among women, 1 and most oncologists routinely provide care for women with this disease. During the past decade, considerable changes have occurred in breast cancer management as new options for evaluating and managing breast tumors have become available. These innovations have contributed to a 2.2% annual decline in breast cancer mortality since 1990. 2 However, they have also spawned a large body of information that oncologists must evaluate and incorporate into daily practice.
Clinical practice guidelines assist by systematically evaluating new evidence and developing consensus on integrating changes into disease management. 3 Guideline recommendations set an important standard of care for early breast cancer. Studies of oncology practice patterns have identified several areas of discrepancy with well-established guideline recommendations, such as underuse of systemic adjuvant therapy. [4] [5] [6] Adherence to other recommendations have been less well studied.
Furthermore, studies that use retrospective methods provide little insight into the adoption of recent guideline updates. In an effort to identify important targets 
Results

Physician Demographics
Surveys were sent to a sample of 900 practicing oncologists in the United States drawn randomly from the 2006 American Medical Association (AMA) Physician Master File. Of these, 155 were returned as undeliverable, and 205 responses were collected (28% response rate). Respondents were included in the analysis if they specialized in medical oncology or hematology-oncology, saw at least 10 patients per week, and estimated that at least 5% of their patients had breast cancer. Twenty-one respondents who did not meet these criteria were excluded, and a sample of the 184 remaining responses was used for analysis.
Characteristics of respondents are presented in Table 1 . The respondents reported a median of 20 years since medical school graduation and 80 patients seen per week. They reported that 25% of their patients had breast cancer. Of the respondents, 60% held an academic appointment, and 13% practiced at a National Cancer Institute-designated cancer center. Oncologists with higher portions of patients with breast cancer were more likely to be women (P < .001) and to have an academic appointment (P < .001). The analysis sample was compared with medical oncologists in the 2006 AMA Physician Master File and found to be similar with respect to years since medical school graduation. However, the sample had a higher proportion of women (28% vs. 21%; P = .02).
Practice Patterns
Baseline Assessment: The survey asked oncologists about their approach to breast cancer evaluation in 2 separate case scenarios ( 
Methods
Survey Development
A survey containing 5 case vignettes to examine current practice patterns of medical oncologists in the United States in the diagnosis and management of early breast cancer was developed in conjunction with an oncologist with expertise in cancer treatment guidelines (Cases 1-5; Appendix A). This strategy has been shown to be an effective and cost-efficient method for rapidly assessing physicians' clinical decision-making. 7, 8 The case vignettes featured women with early breast cancer (stage I or II) and provided a context to examine clinical decision-making. Questions were designed to assess oncologists' choices in assessment, treatment, and follow-up surveillance relative to the 2007 version of the NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (to view the most recent version of these guidelines, visit the NCCN Web site at NCCN.org). 9 Additional survey items examined oncologists' perceptions about resources used to guide chemotherapy selection, the importance of guidelines in varying aspects of breast cancer care, and demographic characteristics. The 27-item survey was distributed by email and fax to a random sample of U.S. oncologists between July and August of 2007. A $50 gift card was offered as an incentive for survey completion.
Statistical Analysis
Descriptive and inferential statistics were performed using SPSS V.15.0 (SPSS, Inc., Chicago, IL). Chisquare tests were performed for categoric data, and t-tests were used on normally distributed continuous data. These tests were conducted using a level of statistical significance of .05. Responses to 10 survey items examining clinical decision-making were coded relative to NCCN guidelines recommendations and used to assess adherence. Chi-square tests were performed to explore possible associations between guideline adherence and demographic characteristics such as years in practice, volume of patients with breast cancer seen per week, and practice type. atic and whose blood count, liver function tests, and chest radiograph show no abnormalities. Consistent with NCCN recommendations, 85% of oncologists considered further testing by fluorescence in-situ hybridization (FISH) to be indicated. Although considered inappropriate by the NCCN guidelines, 34% of oncologists again favored further assessment with PET scanning in this context.
To assess how oncologists approached axillary node staging, respondents were asked which axillary node sampling method should be used to manage a woman with clinical stage IIA (T2N0) breast cancer when breast preserving treatment using neoadjuvant therapy is planned (Case 2). Sentinel node biopsy before neoadjuvant treatment was the preferred approach (51%), but 25% of respondents would perform sentinel biopsy after completing therapy, and an additional 24% would opt for axillary node dissection at the time of definitive surgery. Therapeutic Selection: Oncologists' perceptions about primary therapy in early breast cancer were explored in 2 scenarios. The first (Case 2) described a premenopausal woman with a 4-cm, stage IIA, estrogen receptor (ER)/ progesterone receptor (PR)-positive/ HER2-positive lesion who wants breast-conserving therapy. Neoadjuvant therapy in an attempt to allow lumpectomy was considered the best option by 84% of oncologists, but 11% considered total mastectomy with concurrent transverse rectus abdominus musculocutaneous (TRAM) reconstruction a more desirable option despite the patient's stated preference.
A second scenario (Case 4) discussed a 51-yearold premenopausal woman with no stated preference about breast conservation who has a 2.5-cm stage IIB infiltrating ductal carcinoma that is hormone-receptor positive and HER2 negative. In this context, a larger proportion of oncologists considered mastectomy to be the most appropriate therapy (35%); however, most still favored neoadjuvant chemotherapy (54%).
Respondents were also asked about next steps for a 60-year-old woman initially staged with IIA (cT2, cN0) cancer who underwent mastectomy with immediate reconstruction and was restaged with IIIA (pT2, pN2a, cM0) cancer (Case 5). In this scenario, 82% of oncologists considered the appropriate next step to be radiation therapy to the chest wall, axilla, and supraclavicular areas, consistent with guideline recommendations. An additional 15% favored performing PET, a guideline-inconsistent choice.
The survey explored management of older women in a case describing a frail 75-year-old woman with significant comorbidities who underwent lumpectomy for stage I ER/PR-positive/HER2-negative breast cancer (Case 3). Adjuvant hormonal therapy was considered appropriate by 93% of oncologists. Although radiation therapy is considered optional for older women with favorable tumors, 54% favored its inclusion in adjuvant therapy in this context. Therapeutic Management: NCCN guidelines recommend percutaneous clip placement in a breast tumor before starting neoadjuvant chemotherapy. When asked what additional steps should be undertaken before neoadjuvant therapy in a woman with a large stage IIA tumor (Case 2), 64% of oncologists noted the need for clip placement, but 22% again suggested PET scanning. Because hormonal therapy is influenced by menopausal status, oncologists were asked what criteria they use to determine menopausal status in a woman completing a 5-year course of tamoxifen therapy (Case 4). Consistent with NCCN guidelines, 67% of oncologists would determine current ovarian function by evaluating follicular stimulating hormone (FSH) and estradiol levels; however, 27% would use the interval since last menses, a less reliable approach. Surveillance: A question was also developed to assess the approach to monitoring a patient with stage IIIA breast cancer who completed therapy (Case 4). Almost all respondents indicated that they would regularly obtain a history and physical (98%); 22% would also monitor CA 15-3, and 16% would order semi-annual chest radiographs.
Resources Used to Guide Chemotherapy Selection
To determine the importance of guidelines in decision making, respondents were asked which resources they typically use to guide chemotherapy selection for a premenopausal woman with stage IIA (T2N0) breast cancer that is hormone-receptor positive and HER2 positive (Figure 1 ). Among the 6 information resources included, most respondents (84%) indicated that they would use NCCN or other guidelines and (60%) seek opinions from experts or colleagues. The strong preference for clinical practice guidelines showed no correlation with oncologists' demographic characteristics.
Important Guidelines and Treatment Algorithms
Oncologists were asked to rate the importance to dayto-day practice of guidelines or treatment algorithms on 5 specific aspects of breast cancer care (Table 3) . On average, oncologists considered all topics to be highly important, with additional guidance on treatment options for pregnant women receiving the highest mean rating (7.46 on a 10-point Likert scale).
Specialization in Breast Cancer Care
The impact of specializing in breast cancer care was examined by comparing results from oncologists seeing 25% or fewer patients with breast cancer (Low BC) with those seeing higher proportions (Hi BC). Hi BC oncologists showed a trend toward more guideline-consistent care in baseline assessment (P = .07) and axillary node management (P = .09). Hi BC oncologists were also more likely to favor neoadjuvant chemotherapy over total mastectomy for a large stage IIA breast cancer (P = .02). Hi BC oncologists did not otherwise exhibit guideline-concordant choices to any greater extent than Low BC oncologists. Similarly, Hi BC and Low BC oncologists were similar in the resources used to guide therapeutic treatment selection and perceived importance of guidelines on potential future topics. DX assay to determine therapy for ER-negative cancer. The 2007 NCCN guidelines allow the use of the Oncotype DX assay as a category 2B recommendation in small, ER-positive tumors with unfavorable prognostic features. 9 However, no strong evidence is available to support its use in women with ER-negative tumors, suggesting that education is needed on this issue.
Nearly 10% of oncologists chose to administer trastuzumab to a woman whose tumor was 2+ HER2-positive by immunohistochemistry, but later found to be HER2-negative by FISH. This finding is difficult to explain, unless one assumes that respondents doubted the accuracy of FISH testing in their laboratories. Beyond these issues, the survey identified other areas of deficient information. One-third of oncologists did not recognize the need to place clips in the tumor bed before neoadjuvant chemotherapy in a woman with a large stage IIA tumor. Almost one-third of respondents would use time since the last menses to determine menopausal status before starting an aromatase inhibitor rather than serial testing of luteinizing hormone, FSH, and estradiol as recommended by the NCCN guidelines. The use of tumor markers and semi-annual chest radiographs for follow-up was continued by approximately onefifth of respondents despite guideline recommendations to the contrary.
Findings from this study are consistent with retrospective assessments of breast cancer care quality. These studies typically found adherence to quality measures in most cases but also showed substantial variation across measures and suggested opportunities to improve care. 6, [15] [16] [17] Few studies have explored which determinants of non-adherence to early-stage breast cancer care are most consequential. Given this void, the framework established by Cabana et al. 18 that outlines impediments to guideline implementation may be instructive. Being aware of and valuing the overall guidelines are clear prerequisites for guideline implementation. That oncologists are unaware of the guidelines themselves seems unlikely, since a large majority indicated use of them to inform treatment decisions. However, guidelines typically contain hundreds of specific recommendations. 19 Some of these are contained in the treatment algorithms, which are designed for quick reference. Although oncologists may be familiar with the information
Discussion
Most respondents showed practice choices for early breast cancer management that adhere to NCCN Clinical Practice Guidelines in Oncology recommendations in several areas. This is encouraging because several studies suggest that adherence to breast cancer guidelines may improve patient outcomes, enhance quality of life, and help contain health care costs. [10] [11] [12] [13] Surveyed oncologists significantly agreed with the guidelines on the use of MRI to evaluate a young, high-risk woman and the use of FISH testing to clarify equivocal HER2 status by immunohistochemistry. Surgical therapy and radiation therapy reported were also largely concordant with guideline recommendations.
However, in several areas, reported practice patterns differed significantly from published guidelines. Most significant of these was the use of PET scans. Responses suggest that PET scan is commonly used in initial assessment and evaluation of therapeutic response. Prospective trial data evaluating the benefit of PET scans using fluorine-18 fluorodeoxyglucose (FDG) on early-stage breast cancer outcomes are lacking but should be available soon. An NCCN Task Force convened in 2007 recommended against PET scans for diagnosis, staging in patients with clinical early-stage disease, or surveillance after therapy.
14 Although PET is valuable in certain types of malignancy and in advanced breast cancer, findings suggest overuse in early-stage breast cancer care.
Another area in which practice patterns differed from guidelines recommendations is use of Oncotype contained in these schematics, they may be less acquainted with other important recommendations that are not as prominent. Thus, fewer oncologists may be aware of recommendations describing criteria for establishing menopausal status, clip placement before neoadjuvant chemotherapy, or options to omit radiation therapy in certain older women with early breast cancer. Another potential explanation of discordance is disagreement with specific recommendations. This may explain the observed non-adherence to NCCN recommendations against the use of PET scans in early breast cancer care. Oncologists may have increasing personal experience with PET technology and exposure to the growing number of small-scale studies favorably describing new applications. They may give greater credence to these influences than to the guideline recommendations on this topic.
System barriers can further hinder guideline implementation, such as cost and availability. Finally, the unique characteristics of age, comorbidities, and personal preferences may make guideline implementation inappropriate for some patients. The case vignettes used in this survey sought to minimize these influences; thus, adherence rates in actual clinical practice may be lower than those reported.
Several strategies can be used to address the knowledge and practice gaps observed in this study. Among these strategies is CME programming, which may be a particularly important mechanism for disseminating recent additions to the guidelines. Quality monitoring at the physician level can also enhance adherence and may significantly improve processes of cancer care. 16 Additional studies exploring the reasons for physician non-adherence and barriers to implementation may provide further insight about which interventions will be most effective.
This study includes several limitations. First, although the use of case vignettes has been shown to provide a valid and reliable measure of physician actual practice patterns, 7, 8 it is a surrogate measure of knowledge and practice patterns. However, we believe it allows rapid assessment of clinical decisionmaking relative to recent guidelines updates and exploration of issues for which quality measures are lacking. Second, the relatively small response rate and limited ability to match oncology respondents to AMA database demographics may hinder the generalizability of findings. Third, this study used a cross-sectional design and did not explore potential determinants for responses. To establish causal inferences, further study using a different design or focus would be needed.
Conclusions
Oncologists appear to make guideline-consistent choices in many aspects of early breast cancer care, but significant divergence occurs in some areas. Oncologists may be unclear about how to optimally use emerging innovations and how to best manage older patients. The NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (to view the most recent version of the these guidelines, visit the NCCN Web site at NCCN.org) are a trusted resource that can help clarify areas of confusion. However, current guidelines cover a great deal of information, and key details can be easily overlooked. Education about guidelines-consistent care that highlights important details and summarizes the evidence on emerging issues may significantly increase the quality of breast cancer care and ultimately improve patient outcomes.
